Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109765
Title:
Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Authors:
Bazill, G W; Dexter, T Michael
Abstract:
We investigated the effect of a number of platelet activating factor antagonists on cell killing by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphoryl choline (ET-18-OCH3). Of six platelet activating factor antagonists tested, four were found to protect WEHI-3B leukemic cells against cell death induced by ET-18-OCH3. Certain other compounds, not platelet activating factor antagonists, had similar protective effects. The protective compounds were all lipophilic weak bases. We describe experiments that indicate that these compounds protect by inhibition of endocytic uptake of ET-18-OCH3. Sensitive cells showed rapid endocytic uptake, whereas in resistant cells, uptake was slow. Uptake of ET-18-OCH3 could be suppressed by inhibitors of endocytosis such as chloroquine, monensin, and vinblastine. We conclude that one of the principal determinants of sensitivity or resistance to ether lipids may be the rate at which cells take them up by endocytosis.
Affiliation:
Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.
Citation:
Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. 1990, 50 (23):7505-12 Cancer Res.
Journal:
Cancer Research
Issue Date:
1-Dec-1990
URI:
http://hdl.handle.net/10541/109765
PubMed ID:
2253199
Type:
Article
Language:
en
ISSN:
0008-5472
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBazill, G Wen
dc.contributor.authorDexter, T Michaelen
dc.date.accessioned2010-08-17T13:30:19Z-
dc.date.available2010-08-17T13:30:19Z-
dc.date.issued1990-12-01-
dc.identifier.citationRole of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells. 1990, 50 (23):7505-12 Cancer Res.en
dc.identifier.issn0008-5472-
dc.identifier.pmid2253199-
dc.identifier.urihttp://hdl.handle.net/10541/109765-
dc.description.abstractWe investigated the effect of a number of platelet activating factor antagonists on cell killing by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphoryl choline (ET-18-OCH3). Of six platelet activating factor antagonists tested, four were found to protect WEHI-3B leukemic cells against cell death induced by ET-18-OCH3. Certain other compounds, not platelet activating factor antagonists, had similar protective effects. The protective compounds were all lipophilic weak bases. We describe experiments that indicate that these compounds protect by inhibition of endocytic uptake of ET-18-OCH3. Sensitive cells showed rapid endocytic uptake, whereas in resistant cells, uptake was slow. Uptake of ET-18-OCH3 could be suppressed by inhibitors of endocytosis such as chloroquine, monensin, and vinblastine. We conclude that one of the principal determinants of sensitivity or resistance to ether lipids may be the rate at which cells take them up by endocytosis.en
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectMyeloid Leukaemaien
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAzepines-
dc.subject.meshCell Survival-
dc.subject.meshChloroquine-
dc.subject.meshDiltiazem-
dc.subject.meshDrug Synergism-
dc.subject.meshEndocytosis-
dc.subject.meshFurans-
dc.subject.meshHumans-
dc.subject.meshHydroxyzine-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshMice-
dc.subject.meshNifedipine-
dc.subject.meshPhospholipid Ethers-
dc.subject.meshPlatelet Activating Factor-
dc.subject.meshPyridines-
dc.subject.meshQuinidine-
dc.subject.meshQuinine-
dc.subject.meshSodium Fluoride-
dc.subject.meshThiazoles-
dc.subject.meshTriazoles-
dc.subject.meshVerapamil-
dc.titleRole of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.en
dc.typeArticleen
dc.contributor.departmentDepartment of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, United Kingdom.en
dc.identifier.journalCancer Researchen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.